Physician profile
William Peterson
NPI 1144419227
$2,295.17
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $1,157 · 2021: $393 · 2022: $57.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,152.39 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $205.29 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $183.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $131.21 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $129.81 | 2020-2021 | |
| Emd Serono, INC. | $98.99 | 2019-2021 | |
| Genentech USA, INC. | $93.42 | 2019-2020 | |
| Biogen, INC. | $74.18 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $53.99 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $37.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.23 | 2021 | |
| Genzyme Corporation | $29.42 | 2019-2020 | |
| Eisai INC. | $24.47 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.87 | 2020 | |
| Mallinckrodt Enterprises LLC | $18.55 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $13.16 | 2022 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$397,416.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.